Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 <i>In Vitro</i>
Karen Anbro Gammeltoft, Yuyong Zhou, Carlos R. Duarte Hernandez, Andrea Galli, Anna Offersgaard, Rui Costa, Long V. Pham, Ulrik Fahnøe, Shan Feng, Troels K. H. Scheel, Santseharay Ramírez, Jens Bukh, Judith M. Gottwein
Abstract
Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PIs) against SARS-CoV-2 and their interactions with remdesivir, the only direct-acting antiviral approved for COVID-19 treatment.
Topics & Concepts
VirologyProteaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakBetacoronavirusProtease inhibitor (pharmacology)In vitroMedicineHepatitis C virusSars virusVirusBiologyEnzymeViral loadInternal medicineGeneticsBiochemistryAntiretroviral therapyDiseaseInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery MethodsCOVID-19 Clinical Research Studies